title: Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary aspergillosis in patients with hematologic malignancies, chronic granulomatous disease, or AIDS.
abstract: The pharmacokinetics, efficacy, and safety of intravenous (iv) itraconazole (2 days at 400 mg/day, 12 days at 200 mg/day), followed by 12 weeks of oral capsules (400 mg/day) were studied in 31 immunocompromised patients with pulmonary invasive aspergillosis. All patients received iv itraconazole (median duration, 14 days), and 26 then received oral itraconazole (median duration, 78.5 days). After receiving iv itraconazole, concentrations increased rapidly, with trough plasma levels > or =250 ng/mL in 91% of patients and in all patients by day 7. Concentrations > or =500 ng/mL were observed in 64% of patients by day 2. Mean trough concentrations after 2 and 14 days were 670 and 850 ng/mL, respectively. Therapeutic levels were maintained after switching to oral capsules. A complete or partial response was seen at the last on-treatment assessment in 15 (48%) of 31 patients, with 6 (19%) showing stable disease. Itraconazole was well tolerated, with no unexpected effects. Overall iv/oral itraconazole was safe and effective in invasive aspergillosis.
authors.affiliation: Department of Haematology, Centre Hospitalier, Universitaire de Dijon, France. denis.caillot8@fnac.net
authors.forename: D
authors.initials: D
authors.lastname: Caillot
authors.forename: H
authors.initials: H
authors.lastname: Bassaris
authors.forename: A
authors.initials: A
authors.lastname: McGeer
authors.forename: C
authors.initials: C
authors.lastname: Arthur
authors.forename: H G
authors.initials: HG
authors.lastname: Prentice
authors.forename: W
authors.initials: W
authors.lastname: Seifert
authors.forename: K
authors.initials: K
authors.lastname: De Beule
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000382:microbiology; D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D001228:Aspergillosis / Q000188:drug therapy*; D005260:Female; D006105:Granulomatous Disease, Chronic / Q000150:complications; D019337:Hematologic Neoplasms / Q000150:complications; D006801:Humans; D016867:Immunocompromised Host; D007275:Injections, Intravenous; D017964:Itraconazole / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D008172:Lung Diseases, Fungal / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged
chemical_list: D000935:Antifungal Agents; D017964:Itraconazole